This activity is particularly relevant in the context of neurodegenerative diseases such as Alzheimer’s disease, where the inhibition of acetylcholinesterase (AChE) is a common therapeutic strategy. Here, ACHE is linked to early-onset autosomal dominant Alzheimer disease.